Ferric Carboxymaltose for Treatment of Anaemia of Cancer in Subjects With Multiple Myeloma Receiving Chemotherapy (AOC-MM)
Randomised Controlled Open-label Study to Evaluate Efficacy & Safety of Intravenous Ferric Carboxymaltose Versus no Treatment in Anaemic Subjects With Multiple Myeloma & Iron Restricted Erythropoiesis Receiving Chemotherapy
Sponsor: Vifor Pharma
Terminated
Lack of Recruitment
Other terminated trials from Vifor Pharma
Other Iron-Deficiency Anemia trials with similar outcome
Listed as NCT01100879, this PHASE4 trial focuses on Iron-Deficiency Anemia and remains terminated or withdrawn. Sponsored by Vifor Pharma, it has been updated 8 times since 2010, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE4
-
Jun 2022 — Jul 2024 [monthly]
Terminated PHASE4
-
Oct 2021 — Jun 2022 [monthly]
Terminated PHASE4
-
Jan 2021 — Oct 2021 [monthly]
Terminated PHASE4
▶ Show 3 earlier versions
-
May 2020 — Jan 2021 [monthly]
Terminated PHASE4
-
Jun 2018 — May 2020 [monthly]
Terminated PHASE4
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE4
First recorded
Mar 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Vifor Pharma
For direct contact, visit the study record on ClinicalTrials.gov .